Oxidatively modified low density lipoprotein (LDL) exhibits several potentially atherogenic properties, and inhibition of LDL oxidation in rabbits decreases the rate of the development of atherosclerotic lesions. In vitro studies have suggested that cellular lipoxygenases may be involved in LDL oxidation, and we have shown previously that 15-lipoxygenase and oxidized LDL are present in rabbit atherosclerotic lesions.
Introduction
The sequence of events leading to clinically significant atherosclerotic lesions in man remains to be established. There is an emerging consensus that the first grossly identifiable lesion is the fatty streak but there may be exceptions. Indeed, there may be not one but rather several alternative pathogenetic sequences. The hallmark of the fatty streak lesion is fat-laden foam cells (1) . Most ofthese represent monocyte/macrophages (2-4), but a significant number also are derived from smooth muscle cells (1) . A consensus is also growing around the proposition that LDL must first undergo one or another modification in its structure and biological properties before it can be taken up rapidly enough by the monocyte/macrophage to gen-erate a foam cell (5) (6) (7) (8) . This hypothesis, while supported by a growing body of in vitro and in vivo evidence, is based largely on studies of cultured cells and on studies in experimental animals. It has not been tested in humans.
One of the modifications of LDL that has been implicated in foam cell formation is oxidative modification (8, 9) . Recently, several lines of evidence have been developed that strongly suggest that oxidative modification of LDL occurs in vivo: (a) immunostaining of rabbit arteries has shown that oxidized LDL and/or oxidation-specific lipid-protein adducts are present in atherosclerotic lesions (10) (11) (12) (13) (14) ; (b) LDL gently extracted from both human and rabbit lesions has the chemical and biological properties of oxidized LDL (15-17); (c) human and rabbit serum contain autoantibodies against epitopes of oxidized LDL (1 1, 18) ; and (d) antioxidant therapy decreases the progression ofatherosclerotic lesions in the Watanabe heritable hyperlipidemic (WHHL)' rabbit (19, 20) .
Various cell types can oxidatively modify LDL in vitro (8, 9, 21, 22) . This process is initiated by lipid peroxidation and is accompanied by breakdown of the LDL apoprotein B, fragmentation of polyunsaturated fatty acids and the conjugation of various reactive aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) to apoprotein B lysine residues (8, 23, 24) . As a result ofthese changes, novel epitopes are generated on the oxidized LDL that are recognized by macrophage receptors (8) .
Studies in this laboratory have led to the proposition that the oxidative modification may be effected by the action of lipoxygenases (LO) in macrophages and in endothelial cells (14, (25) (26) (27) (and possibly other cell types as well). In vitro studies suggest that cellular LO may play an important role in this process: LDL treated with soybean LO and phospholipase A2 closely resembles oxidized LDL (25) and several LO inhibitors can block cell-induced oxidation of LDL (26, 27) . We have shown recently that 1 5-LO mRNA and protein are expressed in macrophage-rich areas of WHHL rabbit atherosclerotic lesions and that the expression colocalizes with the epitopes characteristic for oxidized LDL ( 14) . Atherosclerotic lesions of rabbit and human aorta (28, 29) also show higher levels of 1 5-LO enzymatic activity than corresponding normal arteries.
The pathway by which the oxidized LDL is taken up in monocyte/macrophages involves in part the acetyl LDL receptor, which was first described by Goldstein et al. (5, 30) recently cloned by Kodama and co-workers (31) . Additional receptors may be involved but these remain poorly defined (32, 33 Fig. 3 , A-D, and references I1, 13, 14) . Tissue samples were immediately transferred to formal-sucrose at 4VC (4% paraformaldehyde, 5% sucrose, I mM EDTA, 50 uM butylated hydroxytoluene, pH 7.4). After overnight fixation, samples were paraffin-embedded and serial sections (10 4m) were used for in situ hybridization and immunocytochemical studies (14) . As a positive control for the expression of LDL receptor mRNA, perfusionfixed adrenal glands from New Zealand White rabbits were embedded in paraffin and handled identically. All human and animal studies were approved by the Human Subjects Committee and the Animal Subjects Committee of the University of California, San Diego.
In situ hybridization. The following probes were subcloned into plasmid vectors (37) (14, 42) . Reagents used for riboprobe synthesis were from Promega Biotec except that T3 RNA polymerase was from Stratagene, Inc. After the probe synthesis, cDNA templates were digested with RNAse-free DNAse (Promega Biotec), unincorporated isotope was removed using spin columns (Nu-Clean R50, International Biotech Inc., New Haven, CT), samples were extracted with phenol/chloroform and chloroform, and precipitated with ethanol (14) . The specific activity of the probes varied from 250 to 300 Ci/mmol. Before use, probe sizes were reduced by alkaline hydrolysis (43) to an average length of 250 nucleotides. Probe sizes were confirmed by polyacrylamide gel electrophoresis, and their specificity was tested on Northern blot analysis (37) . The nucleotide sequence of the human acetyl LDL receptor (s) is not yet known, but on Northern blots the bovine acetyl LDL receptor probe recognized mRNA isolated from stimulated human THP-1 cells (31) and the probe was considered suitable for in situ hybridization studies with human tissue.2 To control the 2. See note added in proof at end of this article. specificity ofthe in situ hybridizations two control hybridizations were done routinely in addition to the nonhybridizing sense probe controls (see below): pretreatment of the sections with RNAse A abolished the signal; and human retinoic acid receptor probe used as an irrelevant probe did not hybridize to the sections. In situ hybridizations were done as described previously (14): tissue sections were deparaffinized, digested with proteinase K (I jg/ml, 10 min at 370C; Boehringer-Mannheim Biochemicals, Indianapolis, IN), and acetylated (0.25% acetic anhydride in 0.1 M triethanolamine, 10 min 20'C) (14) . Slides were washed twice in 2 X SSC (I X SSC = 150 mM NaCI, 15 mM Na-citrate, pH 7.0), dehydrated, and dried in vacuo. Each hybridization experiment was done from a set of serial sections using an antisense probe and a corresponding nonhybridizing sense probe. 45 M1 ofhybridization solution (see below) containing 3-6 X 106 cpm/ml ofeach probe was added to the slides and they were hybridized at 50-520C for 14 h (14 Immunocytochemistry. Serial paraffin-embedded sections were used for immunostaining using previously described antibodies: mouse monoclonal antibodies against human macrophages (HAM-56) (44) and smooth muscle cells (HHF-35) (45), guinea pig polyclonal antisera against MDA-and 4-HNE-modified LDL (MAL-2, HNE-6, respectively) (1 1, 18) ; and Sepharose G-purified rabbit (46) and goat antisera against human recombinant 15-LO (14) . Avidin-biotin-horseradish peroxidase system was used for the immunostaining (Vector Laboratories Inc., Burlingame, CA). After immunocytochemistry the slides were counterstained with methyl green.
Results
Human atherosclerotic lesions contained both monocyte-derived macrophages and smooth muscle cells as identified by monoclonal antibodies. An example of a macrophage-rich fatty streak is seen in Fig. 1 : macrophages occupied the upper part of the lesion (Fig. 1 A) , whereas smooth muscle cells were mostly located in the deeper portions of the intima (Fig. 1 B) . The macrophage-rich areas and some smooth muscle cells stained positively with polyclonal antisera against MDA-LDL (Fig. 1 C) and 4HNE-LDL (Fig. 1 D) indicating the presence of oxidized LDL and/or oxidation-specific lipid-protein adducts. The same areas also contained 15-LO protein (Fig. 1 E) . At higher magnification (Fig. 1 F) and MAL-2 ( Fig. 1 G) immunostainings showed a similar intracellular distribution, as previously reported for WHHL rabbit lesions (1 1, 13, 14) . In lesions some intracellular 1 5-LO and MAL-2 immunostaining was also located in cells fulfilling the morphological criteria for smooth muscle cells. In contrast, the normal smooth muscle cells in the media were uniformly negative.
In situ hybridizations with antisense riboprobes showed 15-LO mRNA (Fig. 1, l Fig. 2 A. No expression of LDL receptor mRNA was seen in the same areas (Fig. 2 C) . However, as a positive control, a clear in situ hybridization signal with the LDL receptor probe was detected in a section of rabbit adrenal cortex (47) (Fig. 2 D) . Macrophages found in areas of diffuse intimal thickening already expressed 1 5-LO mRNA and protein and stained positively for oxidation-specific lipid-protein adducts (Fig. 3) . In advanced atherosclerotic lesions the majority of the cells were identified as smooth muscle cells (Fig. 4 A) and only relatively few macrophages were found in these lesions (Fig. 4 B) . However, as in the fatty streaks, the macrophages in these later lesions expressed 15-LO mRNA (Fig. 4 C) and acetyl LDL receptor mRNA (Fig. 4 D) . In general, it should be noted that 1 5-LO mRNA expression was present in all areas occupied by macrophages, whereas expression of the acetyl LDL receptor mRNA was variable, some macrophage-like cells being positive and others negative, suggesting some type of regulation and/or cell subtype specificity in the expression of the macrophage acetyl LDL receptor. As with the other lesions studied (Figs. 1-3 ), these lesions also contained oxidation-specific epitopes, although there was more diffuse staining involving the matrix (data not shown) as shown previously in advanced rabbit lesions ( 13) .
Discussion
These studies show for the first time that human atherosclerotic lesions react with several antibodies directed against epitopes found on oxidized LDL but not on native LDL. These epitopes were predominantly found in macrophage-rich areas of both early fatty streaks and more advanced lesions, but immunostaining was also frequently seen associated with intimal smooth muscle cells, some of them laden with lipid droplets. Most of the immunostaining appeared to be intracellular, suggesting that these epitopes accumulated as a result of continuing uptake of oxidized LDL. Oxidized LDL appears to resist lysosomal degradation and to accumulate in cultured macrophages (32) . However, we have previously shown that LDL eluted from human lesions contains the oxidation-specific epitopes (15) showing that some oxidized LDL is extracellular. It is also possible that further oxidation occurs within the cells after uptake of modified LDL (13) . Sections of aorta that did not contain frank atherosclerotic lesions were negative for epitopes of oxidized LDL, but in areas of diffuse intimal thickening there were often scattered macrophages that reacted positively. As in the case of rabbit lesions, the adventitia at lesion sites also contained oxidation-specific eptiopes (1 1, 13, 14) .
The present results also establish that acetyl LDL receptor mRNA is expressed in macrophage-rich areas of human lesions. These findings, together with the previously published evidence of acetyl LDL receptor function in macrophages isolated from atherosclerotic lesions (34) (35) (36) , suggest that this receptor could be actively involved in the uptake of oxidized LDL in human lesions. In contrast, no mRNA for the native LDL receptor could be detected, further indicating that this receptor is not importantly involved in lipid accumulation in human lesions. Finally, we find that both mRNA for LO and also LO protein colocalize in macrophage-rich lesions along with epitopes characteristic ofoxidized LDL. The comparative in situ hybridization signal for expression of LO in human lesions is less than that previously observed in WHHL rabbits (14) , possibly because the human lesions contain relatively more smooth muscle cells and fewer macrophages.
Several lines ofevidence make it likely that the LO detected is 1 5-LO rather than 5-LO or 1 2-LO: (a) the 1 5-LO antisense probe gave a strong signal whereas the 5-LO antisense probe, used in the same way, gave no detectable signal; (b) the 15-LO signal was detected using stringent conditions (up to 600C) that should have limited cross-reactivity with other messages; (c) the antiserum used to detect LO protein in these sections was raised against pure recombinant human 15-LO protein and does not cross-react with human platelet 12-LO or leukocyte 5-LO; and (d) 1 5-LO metabolites are preferentially generated in both rabbit and human atherosclerotic lesions (28, 29) . However, we cannot rule out the possibility that the probes used in this study, in addition to detecting 1 5-LO mRNA, also detect some 12-LO mRNA because some isoforms of 12-LO are known to be highly homologous to 1 5-LO (48, 49) . The consequences of the action ofeither of these enzymes on LDL, however, would be expected to. be similar, i.e., the propagation reactions and the further modification of the LDL particle is unlikely to be strongly dependent upon the position at which the hydroperoxide is initially introduced into the unsaturated fatty acid. The human lesions studied here were deliberately selected because they contained a relatively large number of foam cells, identified as monocyte-derived by use of a monoclonal antibody specific for monocyte/macrophages. These lesions represent a human counterpart of the macrophage-rich lesions seen in nonhuman primates (50) and rabbits (51) and probably represent a very early stage in human atherosclerosis (52) . It was not possible to quantify the extent to which lesions of the kind selected contribute to the overall aortic atherosclerosis in the patients studied and so the results should not be taken to be necessarily representative. Nevertheless, the generation of human lesions of this kind, expressing the genes studied (1 5-LO and acetyl LDL receptor), is compatible with the possibility that the oxidative modification pathway for fatty streak formation may be operative in early human atherosclerosis.
These human lesions differ in some ways from the lesions previously studied in LDL receptor-deficient rabbits (1 1, 13, 14) . The density of foam cells was considerably less and there was relatively more connective tissue matrix. In addition, there were more smooth muscle cells containing fat droplets. The rabbit lesions, of course, develop rapidly (over a period of months) in animals with plasma cholesterol levels in the 600-800 mg/dl range; by contrast, the human lesions develop in response to a much more moderate degree of hypercholesterolemia and over a much longer time interval. Despite these and other species differences, the lesions have a commonality: the macrophage foam cells contain epitopes reactive to antibodies against oxidized LDL in both cases; they show a high level of expression of 1 5-LO by in situ hybridization; and they are ap- the advanced human lesion, continue to actively express the acetyl LDL receptor and contain oxidation-specific epitopes. Furthermore, because human peripheral monocytes, the precursors of macrophages, do not express 1 5-LO (53, Sigal, E., unpublished data) and because other tissue macrophages (e.g., alveolar macrophages) do not express 1 5-LO (53, and Sigal, E., unpublished data), the findings in the atherosclerotic aorta imply a lesion-specific induction of macrophage 1 5-LO. What factors in the microenvironment elicit this induction remains to be determined. The results are compatible with, but do not prove, the hypothesis that oxidation ofLDL is effected by macrophages expressing a high level of 1 5-LO activity, as appears to be the case in rabbit lesions ( 14) . Once initiation ofthe peroxidation of LDL lipids has begun, the oxidized LDL may be atherogenic by multiple mechanisms (8, (54) (55) (56) (57) and may directly contribute to macrophage lipid accumulation because of enhanced uptake mediated by the acetyl LDL receptor.
The use of in situ hybridization promises to be a valuable way to study the pathogenesis of atherosclerosis using human tissues. This technique allows ascertainment at a microlevel of gene expression in specific cell types at each stage during lesion development. While this approach is still a "static" approach, it at least allows us to ask whether hypotheses generated from experimental studies are compatible with the pathogenesis of the human disease. These studies represent a beginning, however, suggesting that the oxidative modification hypothesis may be relevant to the human disease and that inhibition of LDL oxidation and/or macrophage 15-LO activity might decrease the rate of the development of atherosclerotic lesions.
